Cell-free fetal DNA tests for trisomy show promise in women at lower risk of affected pregnancies: Lower rates of false-positive returns, higher positive predictive value are associated with cfDNA tests versus standard screening panels, say experts

摘要

Atrisomy 21 and 18 screening test that uses cell-free fetal DNA (cfDNA) in pregnant women's blood detects with greater accuracy more fetuses with the disorders than standard screening in a typical U.S.-based population comprised of women at low-risk of having an affected baby, according to recent research.